** Cancer therapy maker Novocure's NVCR.O shares up 4.3% at $16.25

** NVCR says its cancer therapy, Optune Lua, to treat a type of lung cancer, has received a CE (Conformité Européenne) mark in Europe

** The CE marking certifies that a product has met EU health, safety, and environmental requirements

** CE mark approval is based on late-stage study results that showed the therapy, which uses electric fields to kill cancer cells while sparing most nearby healthy cells, also improved survival rates of patients over 8 years - NVCR

** CE mark comes after FDA's approval of Optune Lua in October 2024

** As of last close, NVCR had fallen 45.% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))